Dr. Kellmeyer rejoined Acer as Group Vice President, Clinical Development in August 2021 after serving in a similar role from 2017-2019. She brings to Acer over 25 years of broad cross-functional pharmaceutical development expertise spanning the areas of Clinical Development, Regulatory Affairs, Medical Writing, and Medical Affairs. Over her career, Dr. Kellmeyer has worked in all phases of drug development (pre-clinical through Phase 4 and post-approval) in the therapeutic areas of hepatology, metabolic disorders, and rare diseases. Dr. Kellmeyer has made significant contributions to multiple marketing submissions in the United States and European Union, served as a key team member for two FDA Advisory Committee Meetings, has led clinical development programs, and has been responsible for all externally and internally facing corporate scientific communications. Prior to rejoining Acer, Dr. Kellmeyer served as Vice President of Regulatory Affairs at Madrigal Pharmaceuticals and has held positions of increasing responsibility in Clinical Development and Regulatory Affairs at Intercept Pharmaceuticals, Acer Therapeutics, Amylin Pharmaceuticals, and Gen-Probe. She received a B.S. degree in Biotechnology from Rochester Institute of Technology and a Ph.D. degree in Cellular and Molecular Biology from SUNY Health Science Center at Syracuse.
